A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
NCT00877539
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Males and females 18-60 years
- Mild asthma
- Atopic to allergens
- Unstable asthma
- Smokers or recent ex-smokers
- Recent allergen challenge
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Huntington Beach, California
- Mission Viejo, California
- San Diego, California
- Wheat Ridge, Colorado
- Coeur d'Alene, Idaho
- Normal, Illinois
- South Bend, Indiana
- Baltimore, Maryland
- North Dartmouth, Massachusetts
- North Dartmouth, Massachusetts
- Minneapolis, Minnesota
- Bellevue, Nebraska
- Boys Town, Nebraska
- Omaha, Nebraska
- Winston-Salem, North Carolina
- Oklahoma City, Oklahoma
- Charleston, South Carolina
- Easely, South Carolina
- Dallas, Texas
- Seattle, Washington
- Tacoma, Washington
- Juiz de Fora,
- Porto Alegre,
- Porto Alegre,
- Porto Alegre,
- Rio de Janeiro - RJ,
- Beijing,
- Beijing,
- Beijing,
- Beijing,
- Changsha,
- Chengdu,
- Chengdu,
- Chongqing,
- Guangzhou,
- Kunming,
- Qingdao,
- Shanghai,
- Shenyang,
- Shenyang,
- Xi'An,
- Guatelama City,
- Guatelmala city,
- Guatelmala City,
- Guatemala City,
- Guatemala city,
- Banglore,
- Chennai,
- Coimbatore,
- Coimbatore,
- Hyderabad,
- Jaipur,
- Nagpur,
- Pune,
- Pune,
- Adachi-ku, Tokyo,
- Ako, Hyogo,
- Chiyoda-ku, Tokyo,
- Chuo-ku, Tokyo,
- Chuo-ku, Tokyo,
- Fujioka, Gunma,
- Himeji, Hyogo,
- Hitachi, Ibaraki,
- Iwamizawa, Hokkaido,
- Kanazawa, Ishikawa,
- Kitakami, Iwate,
- Kitakami, Iwate,
- Koga, Ibaraki,
- Koganei, Tokyo,
- Komaki, Aichi,
- Kunitachi, Tokyo,
- Mito, Ibaraki,
- Osaka, Osaka,
- Ota-ku, Tokyo,
- Sapporo, Hokkaido,
- Sendai, Miyagi,
- Sendai, Miyagi,
- Setagaya-ku, Tokyo,
- Takasaki, Gunma,
- Tomakomai, Hokkaido,
- Toshima-ku, Tokyo,
- Toshima-ku, Tokyo,
- Yao, Osaka,
- Yokohama, Kanagawa,
- Yokohama, Kanagawa,
- Daugavpils,
- Preili,
- Riga,
- Riga,
- Riga,
- Riga,
- Riga,
- Riga,
- Ventspils,
- Monterrey,
- Zapopan,
- Zona Río,
- Callao,
- Lima,
- Lima,
- Krakow,
- Lodz,
- Lodz,
- Ostrow Wielkopolska,
- Poznan,
- Tczew,
- Gatchina (Leningradskaya oblast),
- Moscow,
- Moscow,
- Moscow,
- Moscow,
- St. Petersburg,
- St. Petersburg,
- St. Petersburg,
- Los Angeles, California
- Stockton, California
- Centennial, Colorado
- Denver, Colorado
- Panama City, Florida
- Winter Park, Florida
- Novi, Michigan
- Plymouth, Minnesota
- St. Louis, Missouri
- Bozeman, Montana
- Skillman, New Jersey
- Raleigh, North Carolina
- Cincinnati, Ohio
- Portland, Oregon
- Greenville, South Carolina
- Union, South Carolina
- El Paso, Texas
- San Antonio, Texas
- Florianopolis,
- Porto Alegre,
- Sao Paulo,
- Sao Paulo,
- Chengdu,
- Chongqing,
- Guangzhou,
- Guangzhou,
- Haikou,
- Kunming,
- Nanchang,
- Nanjing,
- Shanghai,
- Shanghai,
- Shanghai,
- Shanghai,
- Xi'An,
- Xi'An,
- Xuzhou,
- Yangzhou,
- Yinchuan,
- Bogota,
- Bogota,
- Bogota,
- Medelin,
- Bamberg,
- Berlin,
- Berlin,
- Berlin,
- Berlin,
- Berlin,
- Frankfurt,
- Hamburg,
- Koblenz,
- Lübeck,
- Rüdersdorf,
- Wiesbaden,
- Witten,
- Ahmedabad,
- Coimbatore,
- Hyderabad,
- Jaipur,
- Jaipur,
- Mumbai,
- Mysore,
- Nagpur,
- Aira, Kagoshima,
- Chuo-ku, Tokyo,
- Fukuoka, Fukuoka,
- Fukuoka, Fukuoka,
- Fukuyama, Hiroshima,
- Habikino, Osaka,
- Hiroshima, Hiroshima,
- Itabashi-ku, Tokyo,
- Iwata, Shizuoka,
- Kanazawa, Ishikawa,
- Kishiwada, Osaka,
- Kitakyushu, Fukuoka,
- Kobe, Hyogo,
- Koto-ku, Tokyo,
- Kyoto, Kyoto,
- Matsusaka, Mie,
- Meguro-ku, Tokyo,
- Minato-ku, Tokyo,
- Minato-ku, Tokyo,
- Morioka, Iwate,
- Naka-gun, Ibaraki,
- Nakano-ku,Tokyo,
- Oita,Oita,
- Osaka-Sayama, Osaka,
- Sapporo, Hokkaido,
- Sendai, Miyagi,
- Seto, Aichi,
- Shinagawa-ku, Tokyo,
- Shizuoka, Shizuoka,
- Toyota, Aichi,
- Urasoe, Okinawa,
- Urasoe, Okinawa,
- Urasoe, Okinawa,
- Yokohama, Kanagawa,
- Yotsukaido, Chiba,
- Mexico City,
- Mexico City,
- Monterrey,
- Lima,
- Lima,
- Lima,
- Lima,
- Lima,
- Bialystok,
- Bydgoszcz,
- Gorzow Wielkopolski,
- Krakow,
- Poznan,
- Sopot,
- Wloszczowa,
- Wroclaw,
- Brasov,
- Brasov,
- Bucharest,
- Bucharest,
- Bucharest,
- Bucharest,
- Bucharest,
- Bucuresti,
- Constanta,
- Iasi,
- Denver, Colorado
- Columbia, Missouri
- Warrensburg, Missouri
- Boys Town, Nebraska
- Canton, Ohio
- Koblenz,
- Rosenheim,
- Wesel,
- Balvi,
- Daugavpils,
- Rezekne,
- Riga,
- Riga,
- Vilnius,
- Vilnius,
- Vilnius,
- Kamnik,
- Ljubljana,
- Maribor,
- Hallein,
- Linz,
- Neumarkt am Wallersee,
- Schlüsslberg,
- Thalheim bei Wels,
- Berlin,
- Berlin,
- Frankfurt,
- Hamburg,
- Hannover,
- Mainz,
- Schwerin,
- Wiesbaden,
- Wiesloch,
- Ivano-Frankivsk,
- Kharkiv,
- Kharkiv,
- Kiev,
- Kiev,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects | |||
Official Title ICMJE | A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects. | |||
Brief Summary | PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Asthma | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 29 | |||
Original Estimated Enrollment ICMJE | 12 | |||
Actual Study Completion Date ICMJE | July 2010 | |||
Actual Primary Completion Date | December 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 60 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United Kingdom | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00877539 | |||
Other Study ID Numbers ICMJE | A9291002 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |